Abstracts tagged "glucocorticoids"

Abstract Number: 1590 • ACR Convergence 2020
Bone Health in ANCA – Associated Vasculitis Patients
Deepa Ragesh Panikkath¹, Sandy Lee² and Christina Downey², ¹Loma Linda University Health, Department of Rheumatology, Loma Linda, CA, ²Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Glucocorticoids (GC) are an important mode of therapy in ANCA associated vasculitis (AAV), and osteoporosis (OP) and fractures are potential adverse effects seen. The…
Abstract Number: 0120 • ACR Convergence 2020
Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases
Giovanni Adami¹, Angelo Fassio², Alessandro Giollo², Luca Idolazzi², Ombretta Viapiana¹, Davide Gatti² and Maurizio Rossini², ¹University of Verona, Verona, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy
Background/Purpose: The aim of the present work is to determine the fracture risk associated with glucocorticoids requiring diseasesMethods: We conducted a retrospective analysis of a nation-wide…
Abstract Number: 1739 • ACR Convergence 2020
Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption
Sofia Pazmino¹, Annelies Boonen², Diederik De Cock¹, Veerle Stouten¹, Delphine Bertrand¹, Johan Joly³, Rene Westhovens⁴ and Patrick Verschueren⁵, ¹KU Leuven, Leuven, Belgium, ²Maastricht University Medical Center, Maastricht, Netherlands, ³University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium, ⁴University Hospitals Leuven, Belgium, Leuven, Belgium, ⁵University Hospital Leuven, Leuven, Belgium
Background/Purpose: Pain remains the highest priority for improvement to patients with Rheumatoid Arthritis (RA). Analgesic prescription in RA was historically a stand-alone approach and afterwards…
Abstract Number: 0126 • ACR Convergence 2020
Immunophenotyping of Peripheral Blood Highlights an Association of Dysregulated Lymphocytes with Patients with Glucocorticoid-induced Osteonecrosis
Kaichi Kaneko¹, Hao Chen¹, Alexandra Krez², Steven Zeng¹, Peter Park¹, Ye-Ji Lee¹, Takayuki Fujii¹, Haemin Kim¹, Sehwan Mun¹, Seyeon Bae¹, Tania Pannellini³, Joseph Lane⁴, Derek Hansen⁴, Douglas Mintz⁵, Richard Bockman², Emily Stein⁶ and Kyung-Hyun Park-Min⁷, ¹Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ²Endocrine Service, Hospital for special surgery, New York, NY, ³Pathology and Precision Medicine Laboratory, Hospital for special surgery, New York, NY, ⁴Orthopedic surgery, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁵Radiology, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁶Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁷Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, Department of Medicine, Weill Cornell Medical College, New York, NY
Background/Purpose: Avascular necrosis (AVN) is a musculoskeletal condition that can result in significant pain and compromised quality of life. The diverse etiologies of AVN have…
Abstract Number: 1743 • ACR Convergence 2020
Perioperative Steroids in Rheumatoid Arthritis Patients Having Total Joint Replacements: Help or Harm?
Tariq Chukir¹, Susan Goodman², Haley Tornberg³, Huong Do⁴, Charlene Thomas⁵, Alana Sigmund³, Peter Sculco⁶, Bella Mehta⁶, Linda Russell⁶, Mark Figgie² and Emily Stein⁷, ¹Weill Cornell Medicine and New York Presbyterian Hospital, New York, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, New York, NY, ⁵Weill Cornell Medicine, New York, ⁶Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁷Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY
Background/Purpose: Optimal perioperative glucocorticoids (GC) dosing for rheumatoid arthritis (RA) patients on chronic GCs undergoing total joint replacement is unknown. Ideal GC dosing prevents perioperative…
Abstract Number: 1152 • 2019 ACR/ARP Annual Meeting
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
JB Boone¹, S. Bobo Tanner ¹ and April Barnado ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteoporosis and clinical fractures compared to healthy controls. Bone loss in…
Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Shintaro Hirata¹, Takuji Omoto ¹, Hiroki Kohno ¹, Hirofumi Watanabe ¹, Kazutoshi Yukawa ¹, Tadahiro Tokunaga ¹, Tatsuomi Kuranobu ¹, Katsuhiro Oi ¹, Yusuke Yoshida ¹, Tomohiro Sugimoto ¹, Sho Mokuda ¹, Keisuke Oda ¹, Takaki Nojima ¹ and Eiji Sugiyama ¹, ¹Hiroshima University, Hiroshima, Japan
Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…
Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…
Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…
Abstract Number: 1876 • 2019 ACR/ARP Annual Meeting
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
Kenneth Saag¹, Michele McDermott ², Jonathan Adachi ³, Willem Lems ⁴, Nancy Lane ⁵, Piet Geusens ⁶, Peter Butler ², Li Chen ², Daria Crittenden ², Robin Dore ⁷ and Stanley Cohen ⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴VU University Medical Centre, Amsterdam, Netherlands, ⁵University of California at Davis Medical Center, Sacramento, CA, ⁶Maastricht University, Maastricht, Netherlands, ⁷Robin K Dore Inc, Tustin, CA, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Denosumab, a monoclonal antibody against RANKL, is approved for the treatment of glucocorticoid (GC) induced osteoporosis (GiOP). In postmenopausal women with osteoporosis, denosumab discontinuation…
Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Ikuko Tanaka¹, Mari Ushikubo ², Misako Konishi ², Yutaro Hayashi ², Satoshi Hama ³, Keisuke Izumi ², Yutaka Okano ², Shigenori Tamaki ⁴ and Hisaji Ohshima ², ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Tokyo Medical Center, Tokyo, Japan, ³tokyo medical center, tokyo, Japan, ⁴Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
Abstract Number: 2675 • 2019 ACR/ARP Annual Meeting
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database
Jennie Best¹, Amanda M. Kong ², Oth Tran ² and Margaret Michalska ¹, ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Cambridge, MA
Background/Purpose: Oral glucocorticoids (OGC) have been the mainstay of treatment for giant cell arteritis (GCA). However, OGCs are associated with several adverse events (AEs). The…
Abstract Number: 2691 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Gary Craig¹, Keith Knapp ², Bob Salim ³, Shalini Mohan ⁴ and Margaret Michalska ⁴, ¹Arthritis Northwest; Discus Analytics, Spokane, WA, ²Discus Analytics, Spokane, WA, ³Axio Research, Seattle, WA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: For patients with giant cell arteritis (GCA) and/or polymyalgia rheumatica (PMR), glucocorticoids are the mainstay of treatment. However, due to the chronic nature of…
Abstract Number: 2694 • 2019 ACR/ARP Annual Meeting
Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis
Rosemary Peterson¹, Rui Xiao ², Hannah Katcoff ¹, Brian Fisher ¹ and Pamela F. Weiss ¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: The effectiveness of IL-1 and IL-6 inhibitors as first-line therapy in patients with new-onset systemic JIA has led to the concept of a “window…
Abstract Number: 2825 • 2019 ACR/ARP Annual Meeting
Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use
Michael George¹, Joshua Baker ², Lang Chen ³, Qufei Wu ², Fenglong Xie ⁴, Huifeng Yun ³ and Jeffrey Curtis ³, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham
Background/Purpose: Glucocorticoids are recommended as short-term bridging therapy in patients with rheumatoid arthritis (RA), but as many as 30-40% of patients remain on glucocorticoids chronically.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].